AU600536B2 - Crystalline salts of {3s(z)}-2-{{{1-(2-amino-4-thiazolyl) -2-{{2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl}-amino-2- oxoethylidene}-amino}oxy}acetic acid - Google Patents

Crystalline salts of {3s(z)}-2-{{{1-(2-amino-4-thiazolyl) -2-{{2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl}-amino-2- oxoethylidene}-amino}oxy}acetic acid Download PDF

Info

Publication number
AU600536B2
AU600536B2 AU81857/87A AU8185787A AU600536B2 AU 600536 B2 AU600536 B2 AU 600536B2 AU 81857/87 A AU81857/87 A AU 81857/87A AU 8185787 A AU8185787 A AU 8185787A AU 600536 B2 AU600536 B2 AU 600536B2
Authority
AU
Australia
Prior art keywords
amino
compound
oxo
dimethyl
oxoethylidene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU81857/87A
Other languages
English (en)
Other versions
AU8185787A (en
Inventor
Edward Morton Cohen
William Henry Koster
William Lawrence Parker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Publication of AU8185787A publication Critical patent/AU8185787A/en
Application granted granted Critical
Publication of AU600536B2 publication Critical patent/AU600536B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU81857/87A 1986-12-19 1987-11-27 Crystalline salts of {3s(z)}-2-{{{1-(2-amino-4-thiazolyl) -2-{{2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl}-amino-2- oxoethylidene}-amino}oxy}acetic acid Ceased AU600536B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/944,283 US4751220A (en) 1986-12-19 1986-12-19 Crystalline salts of [3S(Z)]-2[[[1-(2-amino-4-thiazolyl)-2-[[2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl]amino]-2-oxoethylidene]-amino]oxy]acetic acid
US944283 1997-10-06

Publications (2)

Publication Number Publication Date
AU8185787A AU8185787A (en) 1988-06-23
AU600536B2 true AU600536B2 (en) 1990-08-16

Family

ID=25481130

Family Applications (1)

Application Number Title Priority Date Filing Date
AU81857/87A Ceased AU600536B2 (en) 1986-12-19 1987-11-27 Crystalline salts of {3s(z)}-2-{{{1-(2-amino-4-thiazolyl) -2-{{2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl}-amino-2- oxoethylidene}-amino}oxy}acetic acid

Country Status (25)

Country Link
US (1) US4751220A (enExample)
JP (1) JP2511083B2 (enExample)
KR (1) KR960007534B1 (enExample)
AU (1) AU600536B2 (enExample)
BE (1) BE1000625A3 (enExample)
CA (1) CA1296717C (enExample)
CH (1) CH674009A5 (enExample)
DE (1) DE3743111C2 (enExample)
DK (1) DK671487A (enExample)
ES (1) ES2007766A6 (enExample)
FI (1) FI91757C (enExample)
FR (1) FR2610627B1 (enExample)
GB (1) GB2199033B (enExample)
GR (1) GR871937B (enExample)
HU (1) HU197568B (enExample)
IE (1) IE61325B1 (enExample)
IL (1) IL84521A (enExample)
IT (1) IT1233457B (enExample)
LU (1) LU87076A1 (enExample)
NL (1) NL193639C (enExample)
NZ (1) NZ222599A (enExample)
PH (1) PH23170A (enExample)
PT (1) PT86403B (enExample)
SE (1) SE467782B (enExample)
ZA (1) ZA879031B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US7041650B2 (en) * 2001-07-09 2006-05-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivative salts
WO2003054155A2 (en) * 2001-12-19 2003-07-03 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
CN101724000B (zh) * 2008-10-29 2012-05-30 广东东阳光药业有限公司 一种红霉素的结晶方法
CN113754651B (zh) * 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
CN113975396B (zh) * 2021-11-09 2022-11-29 中国医学科学院医药生物技术研究所 包含β-内酰胺类化合物的药物组合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU588017B2 (en) * 1985-01-28 1989-09-07 E.R. Squibb & Sons, Inc. Process for preparing 4,4-dialkyl-2-axetidinones

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES376380A1 (es) * 1970-01-30 1972-04-16 Roger Lab Procedimiento de obtencion de un nuevo derivado de eritro- micina.
AU8364875A (en) * 1974-08-21 1977-02-10 Hoffmann La Roche Choline and n-methyl-d-glucamine salts of amoxycillin
US4337197A (en) * 1980-10-31 1982-06-29 E. R. Squibb & Sons, Inc. O-sulfated β-lactam hydroxamic acids and intermediates
US4533660A (en) * 1980-10-31 1985-08-06 E. R. Squibb & Sons, Inc. Antibacterial O-sulfated β-lactam hydroxamic acids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU588017B2 (en) * 1985-01-28 1989-09-07 E.R. Squibb & Sons, Inc. Process for preparing 4,4-dialkyl-2-axetidinones

Also Published As

Publication number Publication date
KR880007528A (ko) 1988-08-27
PT86403B (pt) 1990-11-20
US4751220A (en) 1988-06-14
IL84521A (en) 1992-02-16
SE8705068L (sv) 1988-06-20
NZ222599A (en) 1989-09-27
FR2610627A1 (fr) 1988-08-12
FI875159L (fi) 1988-06-20
IE873447L (en) 1988-06-19
IT8722908A0 (it) 1987-12-07
GB8727048D0 (en) 1987-12-23
JPS63165381A (ja) 1988-07-08
DK671487D0 (da) 1987-12-18
DE3743111A1 (de) 1988-06-30
GB2199033B (en) 1990-10-24
IT1233457B (it) 1992-04-02
FR2610627B1 (fr) 1989-12-01
NL8703047A (nl) 1988-07-18
PH23170A (en) 1989-05-19
LU87076A1 (fr) 1988-07-14
FI875159A0 (fi) 1987-11-23
AU8185787A (en) 1988-06-23
PT86403A (en) 1988-01-01
GR871937B (en) 1988-04-26
GB2199033A (en) 1988-06-29
CH674009A5 (enExample) 1990-04-30
CA1296717C (en) 1992-03-03
BE1000625A3 (fr) 1989-02-21
JP2511083B2 (ja) 1996-06-26
KR960007534B1 (ko) 1996-06-05
SE467782B (sv) 1992-09-14
NL193639C (nl) 2000-05-04
HUT45998A (en) 1988-09-28
IL84521A0 (en) 1988-04-29
DK671487A (da) 1988-06-20
HU197568B (en) 1989-04-28
NL193639B (nl) 2000-01-03
IE61325B1 (en) 1994-11-02
DE3743111C2 (de) 1996-04-04
FI91757C (fi) 1994-08-10
SE8705068D0 (sv) 1987-12-18
ZA879031B (enExample) 1988-05-27
FI91757B (fi) 1994-04-29
ES2007766A6 (es) 1989-07-01

Similar Documents

Publication Publication Date Title
EP0266896B1 (en) 7-( (meta-substituted) phenylglycine) 1-carba-1-dethiacephalosporins
HK217196A (en) Diamine salts of clavulanic acid
US4061748A (en) 7-(α-(4-Hydroxy-1,5-naphthyridine-3-carbonamido)-α-phenylacetamido) cephalosporin derivatives
CA1296717C (en) Crystalline salts of [3s(z)]-2[[[1-(2-amino- 4-thiazolyl)-2-[[2,2-dimethyl-4-oxo-1-(sulfooxy)- 3-azetidinyl]-amino]-2-oxoethylidene]-amino]oxy]acetic acid
CA1148949A (en) 1-oxadethiacephalosporin derivatives and the production thereof
US3989693A (en) 7-Methoxy cyclonexadienylureidocephalosporins
US4117126A (en) 7-(α-(4-Hydroxy-1,5-naphthyridine-3-carbonamido)-α-phenylacetamido) cephalosporin derivatives
EP0269087A2 (en) Cephalosporin derivatives, processes for the preparation of the same, intermediates for use in the synthesis of the same, pharmaceutical compositions comprisingthe same, and the use of the same for the manufacture of a medicament having valuable therapeutic and preventative properties
KR100481143B1 (ko) 항균성 치환 7-아실아미노-3-(메틸히드라조노)메틸-세팔로스포린 및 중간체
US3850916A (en) 7-amino-3-(s-(1,2,3-triazole-5-yl)-thiomethyl)-3-cephem-4-carboxylic acid and salts thereof
KR0177844B1 (ko) 항균성 페넴화합물
EP0122155A2 (en) Improvements in or relating to naphthylglycyl cephalosporin derivatives
PL144812B1 (en) Process for preparing novel bis-esters of dicarboxylic acids
US3780032A (en) 7-(d-(alpha-amino-alpha-phenyl-,2-thienyl-and 3-thienylacetamido)-3-(s-(1-methyl-1,2,3-triazol-4-yl)carbonyl)thiomethyl-3-cephem-4-carboxylic acids
US4349551A (en) Penicillin derivatives and compositions containing them
EP0122154A2 (en) Improvements in or relating to benzothienylglycyl cephalosporin derivatives
US5079241A (en) Cephalosporin derivatives and pharmaceutical compositions in which they are present
US4490370A (en) Naphthylglycyl cephalosporin derivatives
US4755596A (en) Optically active carbacephems
JPS6156238B2 (enExample)
KR830001902B1 (ko) 폐니실란산유도체의 제조방법
KR950005303B1 (ko) 세파계 항균제
CA2046771A1 (en) Antibiotic c-3 di-hydroxyphenyl substituted cephalosporin compounds, compositions and method of use thereof
US4761409A (en) Cephem derivatives
US4044047A (en) Intermediates for preparing substituted phenylglycylcephalosporins

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired